European Antitrust Investigations Boosted As AstraZeneca Challenge Fails
This article was originally published in The Pink Sheet Daily
Executive Summary
The Court of Justice of the European Union decision to uphold a €52.5 million ($67.7 million) fine against AstraZeneca for hindering generic competition will encourage the executive Commission to pursue potentially abusive pay-for-delay practices.